Arcutis Biotherapeutics (ARQT) Non-Current Debt (2021 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Non-Current Debt of $109.4 million for Q1 2026, up 1.67% year-over-year from $107.6 million in Q1 2025, and little changed quarter-over-quarter from $109.0 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Non-Current Debt (2021 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Non-Current Debt history runs 6 years deep, the most recent figure standing at $109.4 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 1.67% year-over-year to $109.4 million; the TTM figure through Mar 2026 stood at $109.4 million (up 1.67% YoY), while the FY2025 annual figure was $109.0 million, up 1.64% from the prior year.
- Non-Current Debt for Q1 2026 stood at $109.4 million, roughly flat from $109.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $203.8 million in Q2 2024, with the low at $72.7 million in Q1 2022.
- The 5-year median for Non-Current Debt is $109.4 million (2026), against an average of $147.1 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 173.35% in 2022, then sank 47.66% in 2024.
- Arcutis Biotherapeutics' Non-Current Debt stood at $197.8 million in 2022, then increased by 2.04% to $201.8 million in 2023, then sank by 46.88% to $107.2 million in 2024, then increased by 1.64% to $109.0 million in 2025, then climbed by 0.42% to $109.4 million in 2026.
- Business Quant data shows ARQT's Non-Current Debt at $109.4 million in Q1 2026, $109.0 million in Q4 2025, and $107.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 108.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.90 Mn |
| Mar 31, 2026 | 109.42 Mn |
| Dec 31, 2025 | 108.96 Mn |
| Sep 30, 2025 | 107.50 Mn |
| Jun 30, 2025 | 107.05 Mn |
| Mar 31, 2025 | 107.62 Mn |
| Dec 31, 2024 | 107.20 Mn |
| Sep 30, 2024 | 105.10 Mn |
| Jun 30, 2024 | 203.81 Mn |
| Mar 31, 2024 | 202.80 Mn |
| Dec 31, 2023 | 201.80 Mn |
| Sep 30, 2023 | 200.78 Mn |
| Jun 30, 2023 | 199.77 Mn |
| Mar 31, 2023 | 198.76 Mn |
| Dec 31, 2022 | 197.77 Mn |
| Sep 30, 2022 | 196.75 Mn |
| Jun 30, 2022 | 73.14 Mn |
| Mar 31, 2022 | 72.74 Mn |
| Dec 31, 2021 | 72.35 Mn |